Protein Discovery
Catalog

Definitively identified by our technology, Seer’s growing catalog of more than 10K proteins is only the start.

Our mass spec-based proteomics can push your studies further. Discover biomarker associations, layer new information onto your genomics data, and enrich your biological insights.

What will you find with Seer?

Search our catalog

Protein Discovery Catalog

  • Offers searches by disease association, reactome pathways, protein name, Uniprot keyword, and more
  • Proteins associated with 100,000+ possible biomarkers across 1,900 reactome biological pathways
  • Includes proteins not yet associated with diseases
  • Contains data from Seer Proteograph XT and Thermo Scientific Orbitrap Astral mass spec
  • After requesting catalog access, you’ll receive an email with a personalized link to explore
  • Access is for 30 days


Why leading experts choose Seer to advance their research

The Proteograph platform has unlocked several new research directions that were previously hampered by technical challenges in our lab. For the first time we are able to look comprehensively at longitudinal age-related changes in low volumes of mouse blood and generate unprecedented biomarker signatures of aging-related outcomes. Additionally, we can detect a variety of secreted human protein changes in cell cultures supplemented with 10% FBS, previously only possible in serum-starved samples, enabling a more biologically relevant view of the secretome.
Nate Basisty, Ph.D. LinkedIn
We are very excited to leverage Seer technology to enable deep and fast plasma proteome analysis. The ability to profile thousands of proteins in a discovery manner within an hour from plasma is unprecedented. This capability has redefined how we think about leveraging mass spectrometry on myriad clinical and translational projects.
Joshua Coon, Ph.D. LinkedIn
The combination of Proteograph XT and Orbitrap Astral in my longitudinal plasma sample of astronauts across two missions, pre-flight and post-flight, resulted in identification of over 7,500 proteins, forming the basis for identification of new biomarkers that change after spaceflight. I am thrilled with the performance of Seer’s proteomic platform and my collaboration with the Seer investigators and look forward to continued profiling for future missions.
Christopher Mason, Ph.D. LinkedIn

Legal Notice

THIS INFORMATION IS PROVIDED “AS IS” AND IS NOT COMPREHENSIVE. INDIVIDUAL RESULTS MAY VARY.  NO INFORMATION IS PROVIDED WITH RESPECT TO INDIVIDUAL SAMPLE OR STUDY TYPES, AND THE UNIPROT IDS SELECTED FOR THIS LIST ARE NOT UNIQUE TO AN INDIVIDUAL STUDY.  DISEASE ASSOCIATION IS DERIVED FROM OPEN TARGETS HTTPS://PLATFORM-DOCS.OPENTARGETS.ORG.  SEER HEREBY DISCLAIMS ANY RESPONSIBILITY FOR, OR LIABILITY WITH RESPECT TO, THE CONTENTS OR ACCURACY OF THE INFORMATION OR ITS INTENDED USE, AND NO EXPRESS OR IMPLIED WARRANTY IS PROVIDED.